Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2018; 72(5): 426–431. doi:10.14735/amgh2018426.

Guidelines of the IBD working group of the SGS on the management on the IBD – optimizing biological treatment in the IBD after loos of response

Miloš Greguš Orcid.org  1,2, Tibor Hlavatý Orcid.org  3, Anna Krajčovičová Orcid.org  3, Laura Gombošová Orcid.org  4, Tomáš Koller Orcid.org  5, Martin Huorka Orcid.org  5, Mária Zakuciová Orcid.org  6, Igor Šturdík Orcid.org  3, Pracovná skupina pre IBD SGS

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Silva-Ferreira F, Afonso J, Pinto-Lopes P et al. A systematic review on infliximab and adalimumab drug monitoring: levels, clinical outcomes and assays. Inflamm Bowel Dis 2016; 22 (9): 2289–2301. doi: 10.1097/MIB.0000000000000855.
2. Moore C, Corbett G, Moss AC. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohn‘s Colitis 2016; 10 (5): 619–625. doi: 10.1093/ecco-jcc/jjw007.
3. Steenholdt C, Bendtzen K, Brynskov J et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis 2016; 22 (8): 1999–2015. doi: 10.1097/MIB.0000000000000772.
4. Bátovský M, Jurgoš Ľ, Bielik J. Racionálna liečba chronických zápalov čreva. Metodický list Ústrednej komisie racionálnej farmakoterapie a liekovej politiky MZ SR 2002; 6 (7): 1–4.
5. Greguš M, Huorka M, Lukáč Ľ. Racionálna liečba chronických nešpecifických zápalov čreva. Metodický list Ústrednej komisie racionálnej farmakoterapie a liekovej politiky MZ SR 2007; 11: (5–6).
6. Kužela L, Zakuciová M. Racionálna liečba chronických nešpecifických zápalov čreva. Metodický list racionálnej farmakoterapie a liekovej politiky MZ SR 2012; 15 (5–7).
7. Brown BB. Delphi Process: A methodology used for the elicitation of opinions of experts. [online]. Dostupné z: https: //www.rand.org/pubs/papers/P3925.html.
8. Calvet X, Panés J, Alfaro N et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis 2014; 8 (3): 240–251. doi: 10.1016/j.crohns.2013.10.010.
9. OCEBM Levels of Evidence Working Group. Oxford Centre for Evidence-Based Medicine 2011. [online]. Awailable from: https: //www.cebm.net/2016/05/ocebm-levels-of-evidence/.
10. Howick J, Chalmers I, Glasziou P et al. The 2011 Oxford CEBM Levels of Evidence: Introductory Document. Oxford Centre for Evidence-Based Medicine 2011. [online]. Awailable from: http: //www.cebm.net/index.aspx?o=5653.
11. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4 (4): 355–366. doi: 10.1016/j.crohns.2010.04.004.
12. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn‘s disease: a systematic review. Am J Gastroenterol 2011; 106 (4): 674–684. doi: 10.1038/ajg.2011.60.
13. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn‘s disease: a review. Am J Gastroenterol 2009; 104 (3): 760–767. doi: 10.1038/ajg.2008.88.
14. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroentrol Hepatol 2014; 11 (4): 243–255. doi: 10.1038/nrgastro.2013.253.
15. Sandborn WJ, Colombel JF, Schreiber S et al. Dosage adjustment during long-term adalimumab treatment for Crohn‘s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17 (1): 141–151. doi: 10.1002/ibd.21328.
16. Sorrentino D, Nguyen V, Henderson C et al. Therapeutic drug monitoring and clinical outcomes in immune mediated diseases: the missing link. Inflamm Bowel Dis 2016; 22 (10): 2527–2537. doi: 10.1097/MIB.0000000000000867.
17. Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterology 2015; 15: 178. doi: 10.1186/s12876-015-0408-x.
18. Levesque BG, Greenberg GR, Zou G et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn‘s disease. Aliment Pharmacol Ther 2014; 39 (10): 1126–1135. doi: 10.1111/apt.12733.
19. Roblin X, Marotte H, Rinaudo M et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12 (1): 80–84.e2. doi: 10.1016/j.cgh.2013.07.010.
20. Sipponen T, Savilahti E, Kärkkäinen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn‘s disease. Inflamm Bowel Dis 2008; 14 (10): 1392–1398. doi: 10.1002/ibd.20490.
21. Sipponen T, Savilahti E, Kolho KL et al.  Crohn‘s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn‘s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14 (1): 40–46. doi: 10.1002/ibd.20312.
22. De Vos M, Louis EJ, Jahnsen J et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013; 19 (10): 2111–2117. doi: 10.1097/MIB.0b013e31829b2a37.
23. Kopylov U, Mazor Y, Yavzori M et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18 (9): 1628–1633. doi: 10.1002/ibd.21919.
24. Ungar B, Chowers Y, Yavzori M et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63 (8): 1258–1264. doi: 10.1136/gutjnl-2013-305259.
25. Vande Casteele N, Buurman DJ, Sturkenboom MG et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36 (8): 765–771. doi: 10.1111/apt.12030.
26. Koh DM, Miao Y, Chinn RJ et al. MR imaging evaluation of the activity of Crohn‘s disease. AJR Am J Roentgenol 2001; 177 (6): 1325–1332. 10.2214/ajr.177.6.1771325
27. Qiu Y, Mao R, Chen BL et al. Systematic review with meta-analysis: magnetic resonance enterography vs. computed tomography enterography for evaluating disease activity in small bowel Crohn‘s disease. Aliment Pharmacol Ther 2014; 40 (2): 134–146. doi: 10.1111/apt. 12815.
28. Nguyen DL, Flores S, Sassi K et al. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease. Ther Adv Chron Dis 2015; 6 (3): 147–154. doi: 10.1177/2040622315579621.
29. Singh N, Rosenthal CJ, Melmed GY et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20 (10): 1708–1713. doi: 10.1097/MIB.0000000000000137.
30. Bortlik M, Duricova D, Malickova K et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn‘s disease. J Crohn‘s Colitis 2013; 7 (9): 736–743. doi: 10.1016/j.crohns.2012.10.019.
31. Vande Casteele N, Gils A, Ballet V et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterol J 2013; 1 (Suppl 1) A1.
32. D‘Haens G, Vermeire S, Lambrecht G et al. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn‘s disease: a prospective, randomised, multicentre trial (Tailorix). European Crohn´s and Colitis Organisation – ECCO 2016: Vienna. [online]. Awailable from: https: //www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2016/item/op029-drug-concentration-versus-symptom-driven-dose-adaptation-of-infliximab-in-patients-with-active-crohnix2019is-disease-a-prospective-randomised-multicentre-trial-tailorix.html.
33. Mazor Y, Almog R, Kopylov U et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn‘s disease. Aliment Pharmacol Ther 2014; 40 (6): 620–628. doi: 10.1111/apt.12869.
34. Bodini G, Giannini EG, Savarino V et al. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. Scand J Gastroenterol 2016; 51 (9): 1081–1086. doi: 10.3109/00365521.2016.1157894.
35. Ungar B, Levy I, Yavne Y et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel  diseases. Clin Gastroenterol Hepatol 2016; 14 (4): 550–557.e2. doi: 10.1016/j.cgh.2015.10.025.
36. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72 (12): 1947–1955. doi: 10.1136/annrheumdis-2012-202220.
37. Vande Casteele N, Khanna R, Levesque BG et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn‘s disease. Gut 2015, 64 (10): 1539–1545. doi: 10.1136/gutjnl-2014-307883.
38. Steenholdt C, Bendtzen K, Brynskov J et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn‘s disease. Scan J Gastroenterol 2011; 46 (3): 310–318. doi: 10.3109/00365521.2010.536254.
39. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial. Gastroenterology 2006; 130 (2): 323–333. doi: 10.1053/j.gastro.2005.11.030.
40. Chiu YL, Rubin DT, Vermeire S et al. Serum adalimumab concentration and clinical remission in patients with Crohn‘s disease. Inflamm Bowel Dis 2013; 19 (6): 1112–1122. doi: 10.1097/MIB.0b013e3182813242.
41. Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn‘s disease. Gastroenterology 2009; 137 (5): 1628–1640. doi: 10.1053/j.gastro.2009.07.062.
42. Weisshof R, Ungar B, Blatt A et al. Anti-infliximab antibodies with neutralizing capacity in patients with inflammatory bowel disease: distinct clinical implications revealed by a novel assay. Inflamm Bowel Dis 2016; 22 (7): 1655–1661. doi: 10.1097/MIB.0000000000000797.
43. D‘Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn‘s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106 (2): 199–212. doi: 10.1038/ajg.2010.392.
44. Van Assche G, Vermeire S, Rutgeerts P. Management of loss of response to anti-TNF drugs: Change the dose or change the drug? J Crohn‘s Colitis 2008; 2 (4): 348–351. doi: 10.1016/j.crohns.2008.05.011.
45. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s  disease. Aliment Pharmacol Ther 2011; 33 (9):  987–995. doi: 10.1111/j.1365-2036.2011.04612.x.
46. Steenholdt C, Brynskov J, Thomsen OØ et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014; 63 (6): 919–927. doi: 10.1136/gutjnl-2013-305279.
47. Bortlík M, Ďuricová D, Machková N et al. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol 2016; 51 (2): 196–202. doi: 10.3109/00365521.2015.1079924.
48. Papamichael K, Vande Casteele N, Gils A et al. Long-term outcome of patients with  Crohn’s disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol 2015; 13 (6): 1103–1110. doi: 10.1016/j.cgh.2014.11.026.
49. Steenholdt C, Molazahi A, Ainsworth MA et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47 (5): 518–527. doi: 10.3109/00365521.2012.660541.
50. Waugh AW, Garg S, Matic K et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharm Ther 2010; 32 (9): 1129–1134. doi: 10.1111/j.1365-2036.2010.04446.x.

Credited self-teaching test